- Alkem Laboratories reported a net income of 7.65 billion rupees in Q2, surpassing estimates of 7.23 billion rupees.
- Net income increased by 11% year-on-year.
- Revenue reached 40 billion rupees, a 17% increase year-on-year, beating the expected 37.59 billion rupees.
- Total costs were 32.1 billion rupees, marking a 16% increase from the previous year.
- Finance costs rose by 24% to 350.2 million rupees, higher than the estimated 270.8 million rupees.
- Employee benefits expenses amounted to 7.1 billion rupees, exceeding the estimate of 6.77 billion rupees with a 16% increase year-on-year.
- Other income decreased by 22% to 1.04 billion rupees.
- Analyst ratings include 11 buys, 7 holds, and 5 sells.
A look at Alkem Laboratories Ltd Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 4 | |
| Growth | 4 | |
| Resilience | 5 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 4.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Alkem Laboratories Ltd, a pharmaceutical company, shows a promising long-term outlook based on the Smartkarma Smart Scores. With a strong resilience score of 5, the company demonstrates the ability to adapt and withstand market challenges effectively. Additionally, Alkem scores well in both growth and momentum, with scores of 4 and 5 respectively, indicating a positive trajectory for expansion and market performance. This positions the company favorably for future development and sustained growth in the pharmaceutical industry.
Furthermore, Alkem Laboratories Ltd excels in dividend payouts with a score of 4, showcasing a commitment to rewarding its investors. While the value score of 2 suggests room for improvement in terms of stock valuation, the company’s overall performance across other key factors bodes well for its long-term sustainability and success.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
